Spend-driver attribution & rebate forecasting
Where is the next $1B coming from? Per-state break-out by drug class shows that GLP-1 spend grew faster than total Rx volume in 31 states. The 12-month SARIMA + Prophet ensemble flags states whose budgets are mis-forecasting GLP-1 exposure.
Forecast · cohort